PRECISION MEDICINE MARKET ANALYSIS

Key Developments

• On February 7, 2024, Exscientia plc, a pharmaceutical technology company, announced the initiation of EXCYTE-2, an observational clinical study in acute myeloid leukemia (AML) to look into the relationship between ex vivo drug response (EVDR) measured in primary blood or bone marrow samples using the company's deep learning, single cell precision medicine platform and actual patient clinical response.
• In May 2023, Google Cloud, a suite of cloud computing services from Google, launched two new Artificial intelligence (AI)-powered life sciences solutions to expedite drug discovery and precision medicine for biotech companies, pharmaceutical enterprises, and public sector organizations. The Target and Lead Identification Suite, which is available worldwide, assists researchers in better identifying the role of amino acids and predicting the structure of proteins, while the Multiomics Suite speeds up the identification and interpretation of genetic data, allowing corporations to build precision medicines.
• In April 2023, The Barcelona Supercomputing Center - Centro Nacional de Supercomputación (BSC-CNS), a public research center, and Fujitsu Limited, a Japan-based multinational information and communications technology company, signed a dual collaboration agreement to promote personalized medicine by leveraging clinical data and to advance quantum simulation technologies using tensor networks.
• In April 2023, Merck, a multinational pharmaceutical company known as MSD outside of the U.S. and Canada, and Prometheus Biosciences, Inc., announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus Biosciences, Inc., a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products.